

Nilvax Formulation

Version 1.1	Revision Date: 05.03.2024		S Number: 306339-00002	Date of last issue: 04.12.2023 Date of first issue: 04.12.2023
SECTION	1. IDENTIFICATION			
Othe	Other means of identification		Nilvax (A3832)	
Man	ufacturer or supplier's o	deta	ils	
Com	pany	:	MSD	
Addr	ess	:		, 6th floor, Ciudad Autonoma rgentina C1013AAP
Telep	phone	:	908-740-4000	
Eme	rgency telephone	:	1-908-423-6000	
E-ma	E-mail address		EHSDATASTEW	/ARD@msd.com
Reco	Recommended use of the chem			ons on use
	ommended use rictions on use	:	Veterinary produ Not applicable	ict

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification Acute toxicity (Oral)	:	Category 5
Reproductive toxicity	:	Category 2
GHS label elements Hazard pictograms	:	
Signal Word	:	Warning
Hazard Statements	:	H303 May be harmful if swallowed. H361d Suspected of damaging the unborn child.
Precautionary Statements	:	 Prevention: P201 Obtain special instructions before use. P202 Do not handle until all safety precautions have been read and understood. P280 Wear protective gloves/ protective clothing/ eye protection/ face protection. Response: P312 Call a POISON CENTER/ doctor if you feel unwell.



Version	Revision Date:	SDS Number:	Date of last issue: 04.12.2023
1.1	05.03.2024	11306339-00002	Date of first issue: 04.12.2023

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Antigen	Not Assigned	>= 1 -< 5
(S)-2,3,5,6-tetrahydro-6-phenylimidazo[2,1- b]thiazoletriylium phosphate	32093-35-9	>= 3 -< 5

SECTION 4. FIRST AID MEASURES

General advice	:	In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	:	If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	:	In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	:	Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.
If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	:	May be harmful if swallowed. Suspected of damaging the unborn child.
Protection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	:	Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media	:	Water spray
		Alcohol-resistant foam
		Carbon dioxide (CO2)
		Dry chemical



Ver 1.1	sion	Revision Date: 05.03.2024		S Number: 306339-00002	Date of last issue: 04.12.2023 Date of first issue: 04.12.2023
	Unsuita media	ble extinguishing	:		
	Specific fighting	hazards during fire	:	Exposure to comb	pustion products may be a hazard to health.
	Hazardo ucts	ous combustion prod-	:	Carbon oxides	
	Specific extinguishing meth- ods		:	cumstances and t Use water spray t	measures that are appropriate to local cir- he surrounding environment. o cool unopened containers. ged containers from fire area if it is safe to do
	Special for fire-f	protective equipment ighters	:	In the event of fire Use personal prot	e, wear self-contained breathing apparatus. ective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec- : tive equipment and emer- gency procedures	Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions :	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g., by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for containment and cleaning up	Soak up with inert absorbent material. For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures	: See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
Local/Total ventilation Advice on safe handling	 Use only with adequate ventilation. Do not breathe mist or vapors. Do not swallow. Avoid contact with eyes. Avoid prolonged or repeated contact with skin.



Version 1.1	Revision Date: 05.03.2024	SDS Number: 11306339-00002	Date of last issue: 04.12.2023 Date of first issue: 04.12.2023
		practice, based assessment	dance with good industrial hygiene and safety on the results of the workplace exposure event spills, waste and minimize release to the
Cond	itions for safe storage	Store locked up	r labeled containers.
Mater	rials to avoid		n the following product types:

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis
(S)-2,3,5,6-tetrahydro-6- phenylimidazo[2,1- b]thiazoletriylium phosphate	32093-35-9	TWA	20 µg/m3 (OEB 3)	Internal
	Further information	ation: Skin		
		Wipe limit	200 µg/100 cm ²	Internal

Engineering measures :	Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip- less quick connections). All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.
Personal protective equipment	

Respiratory protection Filter type Hand protection		If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection. Particulates type
Material	:	Chemical-resistant gloves
Remarks Eye protection	:	Consider double gloving. Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Skin and body protection	:	Work uniform or laboratory coat.



Version	Revision Date:	SDS Number:	Date of last issue: 04.12.2023
1.1	05.03.2024	11306339-00002	Date of first issue: 04.12.2023
Hygie	ene measures	task being period disposable suits Use appropriate contaminated cl : If exposure to cl eye flushing sys working place. When using do Wash contamin The effective op engineering cor appropriate deg	hemical is likely during typical use, provide stems and safety showers close to the not eat, drink or smoke. ated clothing before re-use. beration of a facility should include review of trols, proper personal protective equipment, owning and decontamination procedures, ne monitoring, medical surveillance and the

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	Aqueous solution
Color	:	No data available
Odor	:	No data available
Odor Threshold	:	No data available
рН	:	3,4 - 4,4
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	No data available
Relative vapor density	:	No data available
Relative density	:	No data available
Density	:	No data available



Nilvax Formulation

Versi 1.1	ion	Revision Date: 05.03.2024		S Number: 306339-00002	Date of last issue: 04.12.2023 Date of first issue: 04.12.2023
:	Solubil Wat	ity(ies) ter solubility	:	No data available	9
	Partitio octano	n coefficient: n-	:	Not applicable	
		nition temperature	:	No data available	9
	Decom	position temperature	:	No data available	9
	Viscosi Visc	ity cosity, kinematic	:	No data available	2
	Explos	ive properties	:	Not explosive	
	Oxidizi	ng properties	:	The substance o	r mixture is not classified as oxidizing.
	Molecu	ılar weight	:	No data available	9
	Particle Particle	e characteristics e size	:	Not applicable	

SECTION 10. STABILITY AND REACTIVITY

Reactivity Chemical stability	:	Not classified as a reactivity hazard. Stable under normal conditions.
tions	÷	Can react with strong oxidizing agents.
Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure	:	Skin contact
		Ingestion
		Eye contact
A		

Acute toxicity

May be harmful if swallowed.

Product:

Acute oral toxicity	:	Acute toxicity estimate: 4.173 mg/kg
		Method: Calculation method

Components:

(S)-2,3,5,6-tetrahydro-6-phenylimidazo[2,1-b]thiazoletriylium phosphate:

Acute oral toxicity	: LD50 (Rat): 180 mg/kg
---------------------	-------------------------

LD50 (Mouse): 223 mg/kg



Nilvax Formulation

Version 1.1	Revision Date: 05.03.2024	SDS Number:Date of last issue: 04.12.202311306339-00002Date of first issue: 04.12.2023	
		LD50 (Rabbit): 458 mg/kg	
		LD50 (Rat): 180 mg/kg	
		LD50 (Mouse): 223 mg/kg	
		LD50 (Rabbit): 458 mg/kg	
Acute	inhalation toxicity	: Remarks: No data available	
Acute	e dermal toxicity	: Remarks: No data available	
•••••	corrosion/irritation lassified based on ava	able information.	
Com	ponents:		
(S)-2 Rema		enylimidazo[2,1-b]thiazoletriylium phosphate: : No data available	
	ous eye damage/eye i lassified based on ava		
Com	ponents:		
(S)-2	,3,5,6-tetrahydro-6-pł	enylimidazo[2,1-b]thiazoletriylium phosphate:	
Rema	arks	: No data available	
Resp	iratory or skin sensit	zation	
-	sensitization lassified based on ava	able information.	
•	iratory sensitization lassified based on ava	able information.	
Com	ponents:		
(S)-2 Rema	•	enylimidazo[2,1-b]thiazoletriylium phosphate: : No data available	
	n cell mutagenicity lassified based on ava	able information.	
Com	ponents:		
	3,5,6-tetrahydro-6-pl toxicity in vitro	enylimidazo[2,1-b]thiazoletriylium phosphate: : Test Type: Bacterial reverse mutation assay (AMES Result: negative	3)
		Test Type: Chromosome aberration test in vitro Result: negative	



Nilvax Formulation

	Version 1.1	Revision Date: 05.03.2024	SDS Number: 11306339-0000	Date of last issue: 04.12.2023 Date of first issue: 04.12.2023	
_	Not cl <u>Com</u> (S)-2,		enylimidazo[2,1-k]thiazoletriylium phosphate:	
		cation Route sure time EL	: Mouse : Oral : 2 Years : 80 mg/kg bo : No significa	dy weight adverse effects were reported	
		cation Route sure time EL	: Rat : Oral : 2 Years : 40 mg/kg bc : No significal	dy weight t adverse effects were reported	
	Suspe	oductive toxicity ected of damaging the	unborn child.		
	Com	ponents:			
		3,5,6-tetrahydro-6-ph ts on fertility	: Test Type: T Species: Ra Application Result: No s		
			rescrype.		

Test Type: Three-generation reproduction toxicity study Species: Rat Application Route: Oral Result: No significant adverse effects were reported

Effects on fetal development	:	Test Type: Embryo-fetal development Species: Rat Application Route: Oral Developmental Toxicity: NOAEL: 20 mg/kg body weight Result: Fetotoxicity.
		Test Type: Embryo-fetal development Species: Rabbit Application Route: Oral Developmental Toxicity: LOAEL: 40 mg/kg body weight Result: Fetotoxicity.
Reproductive toxicity - As- sessment	:	Some evidence of adverse effects on development, based on animal experiments.

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

Not classified based on available information.



	05.03.2024		DS Number: 306339-00002	Date of last issue: 04.12.2023 Date of first issue: 04.12.2023
<u>Comp</u>	oonents:			
(S)-2,:	3.5.6-tetrahydro-6-phe	nyli	midazo[2,1-b]thi	azoletriylium phosphate:
	t Organs	:	Blood, Testis	
-	ssment	:		age to organs through prolonged or repeated
Repea	ated dose toxicity			
<u>Comp</u>	oonents:			
(S)-2,:	3,5,6-tetrahydro-6-phe	nyli	midazo[2,1-b]thi	azoletriylium phosphate:
Specie		:	Rat	
NOAE		:	2,5 mg/kg	
	ation Route	÷	Oral 18 Months	
	sure time t Organs	:	Testis	
Specie		:	Dog	
LOAE		:	20 mg/kg	
	ation Route	÷	Oral	
	sure time t Organs	:	18 Months Blood	
raige	lorgans	•	ЫООЦ	
Specie		:	Dog	
LOAE		:	40 mg/kg	
	ation Route	÷	Oral 3 Months	
•				
•	ation toxicity	ahle	information	
Not cla	assified based on availa			
Not cla Exper	assified based on availa			
Not cla Exper	assified based on availa			
Not cla Exper <u>Comp</u>	assified based on availa rience with human exp ponents:	osı	ıre	azoletriylium phosphate:
Not cla Exper <u>Comp</u>	assified based on availa rience with human exp <u>ponents:</u> 3,5,6-tetrahydro-6-phe	osı	u re midazo[2,1-b]thi Symptoms: Nau	azoletriylium phosphate: sea, Vomiting, Headache, Dizziness, hypo-
Not cla Exper <u>Comp</u> (S)-2,3	assified based on availa rience with human exp <u>ponents:</u> 3,5,6-tetrahydro-6-phe	osı	ure midazo[2,1-b]thi	
Not cla Exper <u>Comp</u> (S)-2,: Ingest	assified based on availa rience with human exp <u>ponents:</u> 3,5,6-tetrahydro-6-phe	nyli :	midazo[2,1-b]thi Symptoms: Nau tension	
Not cla Exper <u>Comp</u> (S)-2,: Ingest	assified based on availa rience with human exp <u>ponents:</u> 3,5,6-tetrahydro-6-phe tion 12. ECOLOGICAL INF	nyli :	midazo[2,1-b]thi Symptoms: Nau tension	
Not cla Exper <u>Comp</u> (S)-2,: Ingest CTION	assified based on availa rience with human exp <u>ponents:</u> 3,5,6-tetrahydro-6-phe tion 12. ECOLOGICAL INF	nyli :	midazo[2,1-b]thi Symptoms: Nau tension	
Not cla Exper Comp (S)-2, Ingest CTION Ecoto Comp	assified based on availa rience with human exp oonents: 3,5,6-tetrahydro-6-phe tion 12. ECOLOGICAL INF oxicity oonents:	oosi nyli : ORM	ire midazo[2,1-b]thi Symptoms: Nau tension MATION	sea, Vomiting, Headache, Dizziness, hypo-
Not cla Exper Comp (S)-2,3 Ingest CTION Ecoto <u>Comp</u> (S)-2,3	assified based on availa rience with human exp oonents: 3,5,6-tetrahydro-6-phe tion 12. ECOLOGICAL INF oxicity oonents: 3,5,6-tetrahydro-6-phe	oosi nyli : ORM	ure midazo[2,1-b]thi Symptoms: Nau tension MATION	sea, Vomiting, Headache, Dizziness, hypo-
Not cla Exper Comp (S)-2,3 Ingest CTION Ecoto <u>Comp</u> (S)-2,3	assified based on availa rience with human exp oonents: 3,5,6-tetrahydro-6-phe tion 12. ECOLOGICAL INF oxicity oonents:	oosi nyli : ORM	midazo[2,1-b]thi Symptoms: Nau tension MATION	sea, Vomiting, Headache, Dizziness, hypo- azoletriylium phosphate: atipes (Japanese medaka)): 37,3 mg/l
Not cla Exper Comp (S)-2,3 Ingest CTION Ecoto <u>Comp</u> (S)-2,3	assified based on availa rience with human exp oonents: 3,5,6-tetrahydro-6-phe tion 12. ECOLOGICAL INF oxicity oonents: 3,5,6-tetrahydro-6-phe	oosi nyli : ORM	midazo[2,1-b]thi Symptoms: Nau tension MATION MATION	sea, Vomiting, Headache, Dizziness, hypo- azoletriylium phosphate: atipes (Japanese medaka)): 37,3 mg/l
Not cla Exper Comp (S)-2, Ingest CTION Ecoto Comp (S)-2, Toxici	assified based on availa rience with human exp <u>ponents:</u> 3,5,6-tetrahydro-6-phe tion 12. ECOLOGICAL INFO particity <u>ponents:</u> 3,5,6-tetrahydro-6-phe ty to fish	nyli : ORI	midazo[2,1-b]thi Symptoms: Nau tension MATION MATION	sea, Vomiting, Headache, Dizziness, hypo- azoletriylium phosphate: atipes (Japanese medaka)): 37,3 mg/l 96 h Test Guideline 203
Not cla Exper Comp (S)-2, Ingest CTION Ecoto Comp (S)-2, Toxici	assified based on availa rience with human exp <u>ponents:</u> 3,5,6-tetrahydro-6-phe tion 12. ECOLOGICAL INFO poxicity ponents: 3,5,6-tetrahydro-6-phe ty to fish ty to daphnia and other	nyli : ORI	midazo[2,1-b]thi Symptoms: Nau tension MATION MATION MATION MATION Exposure time: 9 Method: OECD EC50 (Daphnia	sea, Vomiting, Headache, Dizziness, hypo- azoletriylium phosphate: atipes (Japanese medaka)): 37,3 mg/l 96 h Test Guideline 203 magna (Water flea)): 64 mg/l
Not cla Exper Comp (S)-2, Ingest CTION Ecoto Comp (S)-2, Toxici	assified based on availa rience with human exp <u>ponents:</u> 3,5,6-tetrahydro-6-phe tion 12. ECOLOGICAL INFO particity <u>ponents:</u> 3,5,6-tetrahydro-6-phe ty to fish	nyli : ORI	midazo[2,1-b]thi Symptoms: Nau tension MATION MATION MATION MATION Exposure time: 9 Method: OECD EC50 (Daphnia Exposure time: 4	sea, Vomiting, Headache, Dizziness, hypo- azoletriylium phosphate: atipes (Japanese medaka)): 37,3 mg/l 96 h Test Guideline 203 magna (Water flea)): 64 mg/l 48 h
Not cla Exper Comp (S)-2, Ingest CTION Ecoto Comp (S)-2, Toxici	assified based on availa rience with human exp <u>ponents:</u> 3,5,6-tetrahydro-6-phe tion 12. ECOLOGICAL INFO poxicity ponents: 3,5,6-tetrahydro-6-phe ty to fish ty to daphnia and other	nyli : ORI	midazo[2,1-b]thi Symptoms: Nau tension MATION MATION MATION MATION Exposure time: 9 Method: OECD EC50 (Daphnia Exposure time: 4	sea, Vomiting, Headache, Dizziness, hypo- azoletriylium phosphate: atipes (Japanese medaka)): 37,3 mg/l 96 h Test Guideline 203 magna (Water flea)): 64 mg/l



Version 1.1	Revision Date: 05.03.2024	•	DS Number: 1306339-00002	Date of last issue: 04.12.2023 Date of first issue: 04.12.2023			
	Persistence and degradability No data available						
	ccumulative potential						
No da	No data available						
Mobility in soil							
No da	No data available						
Other adverse effects							
No da	No data available						
SECTION	SECTION 13. DISPOSAL CONSIDERATIONS						
Disp	osal methods						
Wast	e from residues	:		of waste into sewer. cordance with local regulations.			
Conta	Contaminated packaging		handling site for	s should be taken to an approved waste recycling or disposal. specified: Dispose of as unused product.			

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Special precautions for user

Not applicable

SECTION 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture Argentina, Carcinogenic Substances and Agents : Not applicable

Registry.	•	Not applicable
Control of precursors and essential chemicals for the preparation of drugs.	:	Not applicable

The ingredients of this product are reported in the following inventories:

AICS	:	not determined



Version 1.1	Revision Date: 05.03.2024	SDS Number: 11306339-00002	Date of last issue: 04.12.2023 Date of first issue: 04.12.2023
DSL		: not determined	
IECSC		: not determined	

SECTION 16. OTHER INFORMATION

Revision Date	: 05.03.2024
Date format	: dd.mm.yyyy

Further information

Sources of key data used to	:	Internal technical data, data from raw material SDSs, OECD
compile the Material Safety		eChem Portal search results and European Chemicals Agen-
Data Sheet		cy, http://echa.europa.eu/

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the



Nilvax Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.12.2023
1.1	05.03.2024	11306339-00002	Date of first issue: 04.12.2023

SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

AR / Z8